These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 35763229)

  • 1. Sentinel Lymph Node Biopsy Alone is Adequate for Chemotherapy Decisions in Postmenopausal Early-Stage Hormone-Receptor-Positive, HER2-Negative Breast Cancer with One to Three Positive Sentinel Lymph Nodes.
    Kantor O; Weiss A; Burstein HJ; Mittendorf EA; King TA
    Ann Surg Oncol; 2022 Nov; 29(12):7674-7682. PubMed ID: 35763229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How Often Do Sentinel Lymph Node Biopsy Results Affect Adjuvant Therapy Decisions Among Postmenopausal Women with Early-Stage HR
    Pilewskie M; Sevilimedu V; Eroglu I; Le T; Wang R; Morrow M; Braunstein LZ
    Ann Surg Oncol; 2022 Oct; 29(10):6267-6273. PubMed ID: 35849294
    [TBL] [Abstract][Full Text] [Related]  

  • 3. To Dissect or Not to Dissect: Can We Predict the Presence of Four or More Axillary Lymph Node Metastases in Postmenopausal Women with Clinically Node-Negative Breast Cancer?
    Farley C; Bassett R; Meric-Bernstam F; Bedrosian I; Caudle A; DeSnyder S; Hunt K; Kuerer H; Singh P; Sun S; Tamirisa N; Teshome M; Hwang RF
    Ann Surg Oncol; 2023 Dec; 30(13):8327-8334. PubMed ID: 37670121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nodal positivity and systemic therapy among patients with clinical T1-T2N0 human epidermal growth factor receptor-positive breast cancer: Results from two international cohorts.
    Weiss A; Martínez-Sáez O; Waks AG; Laws A; McGrath M; Tarantino P; Portnow L; Winer E; Rey M; Tapia M; Prat A; Partridge AH; Tolaney SM; Cejalvo JM; Mittendorf EA; King TA
    Cancer; 2023 Jun; 129(12):1836-1845. PubMed ID: 36951169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Axillary Management After Neoadjuvant Endocrine Therapy for Hormone Receptor-Positive Breast Cancer.
    Kantor O; Wakeman M; Weiss A; Wong S; Laws A; Grossmith S; Mittendorf EA; King TA
    Ann Surg Oncol; 2021 Mar; 28(3):1358-1367. PubMed ID: 32869154
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk Factors for Non-sentinel Lymph Node Metastasis in HR+/HER2- Breast Cancer With cN0.
    Na YM; Park SC; Ryu YJ; Cho JS; Park MH
    Anticancer Res; 2024 Aug; 44(8):3493-3500. PubMed ID: 39060066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Should patients with hormone receptor-positive, HER2-negative breast cancer and one or two positive sentinel nodes undergo axillary dissection to determine candidacy for adjuvant abemaciclib?
    Williams AD; Ruth K; Shaikh SS; Vasigh M; Pronovost MT; Aggon AA; Porpiglia AS; Bleicher RJ
    Cancer; 2024 Apr; 130(7):1052-1060. PubMed ID: 38018862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety comparison between axillary lymph node dissection with no axillary surgery in patients with sentinel node-positive breast cancer: a systematic review and meta-analysis.
    Fan YJ; Li JC; Zhu DM; Zhu HL; Zhao Y; Zhu XB; Wu G; Bai TT
    BMC Surg; 2023 Jul; 23(1):209. PubMed ID: 37495945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Age and Receptor Status Do Not Indicate the Need for Axillary Dissection in Patients with Sentinel Lymph Node Metastases.
    Mamtani A; Patil S; Van Zee KJ; Cody HS; Pilewskie M; Barrio AV; Heerdt AS; Morrow M
    Ann Surg Oncol; 2016 Oct; 23(11):3481-3486. PubMed ID: 27169771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prediction of additional lymph node involvement in breast cancer patients with positive sentinel lymph nodes.
    Pohlodek K; Bozikova S; Meciarova I; Mucha V; Bartova M; Ondrias F
    Neoplasma; 2016; 63(3):427-34. PubMed ID: 26925789
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonsentinel Axillary Lymph Node Status in Clinically Node-Negative Early Breast Cancer After Primary Systemic Therapy and Positive Sentinel Lymph Node: A Predictive Model Proposal.
    Cebrecos I; Mension E; Alonso I; Castillo H; Sanfeliu E; Vidal-Sicart S; Ganau S; Vidal M; Schettini F
    Ann Surg Oncol; 2023 Aug; 30(8):4657-4668. PubMed ID: 36809608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Axillary lymph node dissection vs. sentinel node biopsy for early-stage clinically node-negative breast cancer: a systematic review and meta-analysis.
    Petousis S; Christidis P; Margioula-Siarkou C; Liberis A; Vavoulidis E; Margioula-Siarkou G; Vatopoulou A; Papanikolaou A; Mavromatidis G; Dinas K
    Arch Gynecol Obstet; 2022 Oct; 306(4):1221-1234. PubMed ID: 35249123
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in Surgical Management of the Axilla Over 11 Years - Report on More Than 1500 Breast Cancer Patients Treated with Neoadjuvant Chemotherapy on the Prospective I-SPY2 Trial.
    Boughey JC; Yu H; Dugan CL; Piltin MA; Postlewait L; Son JD; Edmiston KK; Godellas CV; Lee MC; Carr MJ; Tonneson JE; Crown A; Lancaster RB; Woriax HE; Ewing CA; Chau HS; Patterson AK; Wong JM; Alvarado MD; Yang RL; Chan TW; Sheade JB; Ahrendt GM; Larson KE; Switalla K; Tuttle TM; Tchou JC; Rao R; Tamirisa N; Singh P; Gould RE; Terando A; Sauder C; Hewitt K; Chiba A; Esserman LJ; Mukhtar RA
    Ann Surg Oncol; 2023 Oct; 30(11):6401-6410. PubMed ID: 37380911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recommendation for axillary lymph node dissection in women with early breast cancer and sentinel node metastasis: A systematic review and meta-analysis of randomized controlled trials using the GRADE system.
    Huang TW; Kuo KN; Chen KH; Chen C; Hou WH; Lee WH; Chao TY; Tsai JT; Su CM; Huang MT; Tam KW
    Int J Surg; 2016 Oct; 34():73-80. PubMed ID: 27562691
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant chemotherapy and timing of sentinel lymph node biopsy in different molecular subtypes of breast cancer with clinically negative axilla.
    Bi Z; Liu J; Chen P; Liu Y; Zhao T; Wang C; Zhang Z; Sun X; Qiu P; Cong B; Song X; Wang Y
    Breast Cancer; 2019 May; 26(3):373-377. PubMed ID: 30666563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patterns of completion axillary dissection for patients with cT1-2N0 breast cancer undergoing total mastectomy with positive sentinel lymph nodes.
    Schwieger L; Postlewait LM; Subhedar PD; Geng F; Liu Y; Gillespie T; Arciero CA
    J Surg Oncol; 2024 Mar; 129(3):468-480. PubMed ID: 37955191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contemporary Axillary Management in cT1-2N0 Breast Cancer with One or Two Positive Sentinel Lymph Nodes: Factors Associated with Completion Axillary Lymph Node Dissection Within the National Cancer Database.
    Stafford AP; Hoskin TL; Day CN; Sanders SB; Boughey JC
    Ann Surg Oncol; 2022 Aug; 29(8):4740-4749. PubMed ID: 35451727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is routine axillary lymph node dissection needed to tailor systemic treatments for breast cancer patients in the era of molecular oncology? A position paper of the Italian National Association of Breast Surgeons (ANISC).
    Rocco N; Ghilli M; Curcio A; Bortul M; Burlizzi S; Cabula C; Cabula R; Ferrari A; Folli S; Fortunato L; Frittelli P; Gentilini O; Grendele S; Grassi MM; Grossi S; Magnoni F; Murgo R; Palli D; Rovera F; Sanguinetti A; Taffurelli M; Tazzioli G; Terribile DA; Caruso F; Galimberti V
    Eur J Surg Oncol; 2024 Feb; 50(2):107954. PubMed ID: 38217946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial.
    Boughey JC; Suman VJ; Mittendorf EA; Ahrendt GM; Wilke LG; Taback B; Leitch AM; Kuerer HM; Bowling M; Flippo-Morton TS; Byrd DR; Ollila DW; Julian TB; McLaughlin SA; McCall L; Symmans WF; Le-Petross HT; Haffty BG; Buchholz TA; Nelson H; Hunt KK;
    JAMA; 2013 Oct; 310(14):1455-61. PubMed ID: 24101169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The involvement of axillary reverse mapping nodes in patients with clinically node-negative breast cancer.
    Noguchi M; Inokuchi M; Yokoi-Noguchi M; Morioka E
    Breast Cancer; 2022 Mar; 29(2):209-215. PubMed ID: 34591289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.